OpenURL Connection Search

Select item for more details and to access through your institution.

Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
Published in:
British Journal of Haematology, 2022, v. 198, n. 6, p. 1073, doi. 10.1111/bjh.18339
By:
- Dholaria, Bhagirathbhai;
- Mehraban, Nasima;
- Baer, Brittney;
- Long, Nancy;
- Jayani, Reena V.;
- Byrne, Michael T.;
- Kassim, Adetola A.;
- Engelhardt, Brian G.;
- Savani, Bipin N.;
- Oluwole, Olalekan O.
Publication type:
Article
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma.
Published in:
British Journal of Haematology, 2021, v. 194, n. 4, p. 690, doi. 10.1111/bjh.17527
By:
- Oluwole, Olalekan O.;
- Bouabdallah, Krimo;
- Muñoz, Javier;
- De Guibert, Sophie;
- Vose, Julie M.;
- Bartlett, Nancy L.;
- Lin, Yi;
- Deol, Abhinav;
- McSweeney, Peter A.;
- Goy, Andre H.;
- Kersten, Marie José;
- Jacobson, Caron A.;
- Farooq, Umar;
- Minnema, Monique C.;
- Thieblemont, Catherine;
- Timmerman, John M.;
- Stiff, Patrick;
- Avivi, Irit;
- Tzachanis, Dimitrios;
- Kim, Jenny J.
Publication type:
Article
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 10, p. 753, doi. 10.1016/j.clml.2022.05.004
By:
- Jacobs, Miriam T.;
- Jain, Michael D.;
- Gao, Feng;
- Nastoupil, Loretta J.;
- Spiegel, Jay Y.;
- Lin, Yi;
- Dahiya, Saurabh;
- Lunning, Matthew;
- Lekakis, Lazaros;
- Reagan, Patrick M.;
- Oluwole, Olalekan O.;
- McGuirk, Joseph;
- Deol, Abhinav;
- Sehgal, Alison;
- Goy, Andre;
- Hill, Brian T.;
- Andreadis, Charalambos;
- Munoz, Javier;
- Chavez, Julio C.;
- Bennani, N. Nora
Publication type:
Article
ABCL-289: Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S388, doi. 10.1016/S2152-2650(21)01882-6
By:
- Oluwole, Olalekan O.;
- Chen, Jenny MH;
- Chan, Keith;
- Patel, Anik R;
- Jansen, Jeroen P;
- Keeping, Sam;
- Bashir, Zahid;
- Yan Zheng;
- Snider, Julia;
- Locke, Frederick L
Publication type:
Article
Poster: ABCL-289: Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S241, doi. 10.1016/S2152-2650(21)01517-2
By:
- Oluwole, Olalekan O.;
- Chen, Jenny MH;
- Chan, Keith;
- Patel, Anik R.;
- Jansen, Jeroen P.;
- Keeping, Sam;
- Bashir, Zahid;
- Yan Zheng;
- Snider, Julia;
- Locke, Frederick L.
Publication type:
Article
Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S293, doi. 10.1016/j.clml.2018.07.238
By:
- Oluwole, Olalekan O.;
- Bishop, Michael R.;
- Gisselbrecht, Christian;
- Gordon, Leo I.;
- Kersten, Marie José;
- Maloney, David G.;
- Schmitz, Norbert;
- Caballero, Maria Dolores;
- Kuruvilla, John;
- Song, Kevin W.;
- Jacobson, Caron A.;
- Nastoupil, Loretta J.;
- Riedell, Peter;
- Jiang, Yizhou;
- Rossi, John M.;
- Lee, Lillian;
- Cheng, Paul;
- Locke, Frederick L.
Publication type:
Article
Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S276, doi. 10.1016/j.clml.2018.07.203
By:
- Locke, Frederick L.;
- Ghobadi, Armin;
- Lekakis, Lazaros J.;
- Miklos, David B.;
- Jacobson, Caron A.;
- Jacobsen, Eric;
- Braunschweig, Ira;
- Oluwole, Olalekan O.;
- Siddiqi, Tanya;
- Lin, Yi;
- Reagan, Patrick M.;
- Farooq, Umar;
- Deol, Abhinav;
- Bot, Adrian;
- Rossi, John M.;
- Jiang, Yizhou;
- Xue, Allen;
- Go, William Y.;
- Neelapu, Sattva S.
Publication type:
Article
Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S277, doi. 10.1016/j.clml.2018.07.206
By:
- Locke, Frederick L.;
- Ghobadi, Armin;
- Jacobson, Caron A.;
- Jacobsen, Eric;
- Miklos, David B.;
- Lekakis, Lazaros J.;
- Braunschweig, Ira;
- Oluwole, Olalekan O.;
- Lin, Yi;
- Siddiqi, Tanya;
- Deol, Abhinav;
- Reagan, Patrick M.;
- Farooq, Umar;
- Bot, Adrian;
- Jiang, Yizhou;
- Rossi, John M.;
- Xue, Allen;
- Go, William Y.;
- Neelapu, Sattva S.
Publication type:
Article
KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S184, doi. 10.1016/j.clml.2018.07.015
By:
- Shah, Bijal D.;
- Oluwole, Olalekan O.;
- Baer, Maria R.;
- Bishop, Michael R.;
- Holmes, Houston;
- Schiller, Gary J.;
- Donnellan, William;
- O'Dwyer, Kristen M.;
- Mardiros, Armen;
- Rossi, John M.;
- Shen, Tong;
- Xue, Allen;
- Jain, Rajul K.;
- Vezan, Remus;
- Wierda, William G.
Publication type:
Article
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
Published in:
Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1393939
By:
- Oluwole, Olalekan O.;
- Ray, Markqayne D.;
- Zur, Richard M.;
- Ferrufino, Cheryl P.;
- Doble, Brett;
- Patel, Anik R.;
- Bilir, S. Pinar
Publication type:
Article
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Published in:
Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01379-0
By:
- Shah, Bijal D.;
- Ghobadi, Armin;
- Oluwole, Olalekan O.;
- Logan, Aaron C.;
- Boissel, Nicolas;
- Cassaday, Ryan D.;
- Leguay, Thibaut;
- Bishop, Michael R.;
- Topp, Max S.;
- Tzachanis, Dimitrios;
- O'Dwyer, Kristen M.;
- Arellano, Martha L.;
- Lin, Yi;
- Baer, Maria R.;
- Schiller, Gary J.;
- Park, Jae H.;
- Subklewe, Marion;
- Abedi, Mehrdad;
- Minnema, Monique C.;
- Wierda, William G.
Publication type:
Article
Chimeric antigen receptor‐T cell therapies: The changing landscape.
Published in:
2022
By:
- Sengsayadeth, Salyka M.;
- Dholaria, Bhagirathbhai R.;
- Savani, Bipin N.;
- Oluwole, Olalekan O.
Publication type:
Editorial
Role of bridging therapy during chimeric antigen receptor T cell therapy.
Published in:
EJHaem, 2022, v. 3, p. 39, doi. 10.1002/jha2.335
By:
- Bhaskar, Shakthi T.;
- Dholaria, Bhagirathbhai R.;
- Sengsayadeth, Salyka M.;
- Savani, Bipin N.;
- Oluwole, Olalekan O.
Publication type:
Article
Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration.
Published in:
EJHaem, 2022, v. 3, p. 54, doi. 10.1002/jha2.333
By:
- Gatwood, Katie S.;
- Dholaria, Bhagirathbhai R.;
- Lucena, Mariana;
- Baer, Brittney;
- Savani, Bipin N.;
- Oluwole, Olalekan O.
Publication type:
Article

Found: 14